Oct. 1 at 1:36 PM
$BDSX Why I’m Bullish on BDSX:
There is substantial evidence that Biodesix management is actively taking steps to improve company performance ahead of upcoming earnings reports. Initiatives include expanding the sales force, restructuring commercial outreach toward primary care referrals, boosting operational efficiency, executing a reverse stock split, and strengthening their services segment. These actions are designed to drive revenue growth, increase gross margins, and move toward adjusted EBITDA profitability in the near term.
Sales Team Expansion
Biodesix accelerated the growth of its sales force, with the number of representatives rising from 74 to 85 in Q3 and expected to reach 93–97 by Q4 2025. This expansion is intended to improve sales productivity and capture more lung nodule diagnostic test orders, especially from primary care physicians, who now represent a larger portion of the referral base.
Commercial Strategy Shift
The company reconfigured its sales teams into territory-based structures to consolidate efforts across pulmonology and primary care. This has led to a notable increase in test orders and has helped Biodesix penetrate markets with high patient management activity.
Operational & Financial Efficiency
Management has focused on cost controls while enhancing operational efficiency, reflected in improved gross profit margins rising to 80% for Q2 2025 (a 150-basis point increase). The company is also targeting adjusted EBITDA positivity by Q4 2025.
Reverse Stock Split
A 1-for-20 reverse stock split was approved and implemented in September, reducing outstanding shares from 156 million to 8 million. This could help boost share value and attract institutional interest ahead of earnings releases, next Oct 30.
Development Services Growth
Revenue from the Development Services segment grew by 53% year-over-year in Q2, with contract values up 54%, emphasizing the management’s commitment to diversifying revenue streams.
Financial Guidance & Market Positioning
Management remains confident in meeting the full-year revenue guidance of
$80–85 million for 2025, driven by ongoing sales team growth, market expansion, and operational efficiencies. Positive reception from primary care physicians and an expanding contract backlog in biopharmaceutical services underpin this outlook.
